Souhaitez-vous accéder aux communiqués récents ?

The Company expects to initiate first-in-human study in early 2026, with initial data anticipated H2 2026 Clinical Trial Application (CTA) submission marks the advancement of Tangram’s GalOmic RNAi...

Pivotal Phase III liver cancer study enrolling in Europe and Israel RAMAT GAN, Israel, Nov. 18, 2025 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology...

Dublin, Nov. 04, 2025 (GLOBE NEWSWIRE) -- The "Cas12 Protein Market Report 2025" has been added to ResearchAndMarkets.com's offering. The Cas12 Protein Global Market Report 2025 offers essential...

SAN DIEGO, Aug. 14, 2025 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (Nasdaq: VIVS) (the “Company” or “VivoSim Labs”), a pharmaceutical and biotechnology services company that is focused on providing...

Geneva, Switzerland, May 22, 2025 (GLOBE NEWSWIRE) -- Leading health organizations, policymakers, and public health advocates will come together during the 78th World Health Assembly (WHA78) for a...

Yaqrit presents phase 2a data at EASL on oral HE prevention treatment; and an improved HE patient staging tool approved for use by FDA in HE phase 3

NIHR grant funds pivotal trial for Yaqrit's liver support device, DIALIVE, with potential to resolve life-threatening condition and impact survival.

Yaqrit strengthens board and senior management with seasoned industry leaders. Poised to implement late stage clinical strategy in advanced liver disease.

Washington, D.C., Feb. 01, 2025 (GLOBE NEWSWIRE) -- As rural healthcare access shrinks across the United States and remains limited worldwide, Global Liver Institute (GLI) is shining a spotlight on...

SAN DIEGO, Jan. 10, 2025 (GLOBE NEWSWIRE) -- A class action lawsuit has been filed on behalf of all persons and entities who purchased BioAge Labs, Inc. (NASDAQ: BIOA) (“BioAge” or the “Company”)...